apellis pharmaceuticals is an early stage biotechnology company applying immunotherapy to auto-immune diseases, with an initial emphasis on diseases of the lungs such as asthma and chronic obstructive pulmonary disease (copd), diseases of the retina such as age-related macular degeneration (amd), and rare hematological diseases such as paroxysmal nocturnal hemoglobinuria (pnh). apellis believes that targeting a key element in the immune system called the complement system can have profound disease modifying benefits. we call this approach complement immunotherapy.
Company profile
Ticker
APLS
Exchange
Website
CEO
Cedric Francois
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Apellis Australia Pty Ltd. • Apellis Austria GmbH • Apellis Bermuda Ltd. • Apellis Canada Inc. • Apellis Cayman Holdings Limited • APL DEL Holdings LLC • APL DEL Holdings • Apellis Europe • Apellis Germany GmbH • Apellis France S.A.S. ...
APLS stock data
Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
29 Feb 24
S-8
Registration of securities for employees
27 Feb 24
8-K
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Departure of Directors or Certain Officers
22 Jan 24
8-K
Apellis Announces Preliminary Fourth Quarter and Full Year 2023 U.S. Net Product Revenues
8 Jan 24
8-K
Other Events
14 Dec 23
8-K
Regulation FD Disclosure
1 Dec 23
UPLOAD
Letter from SEC
22 Nov 23
CORRESP
Correspondence with SEC
20 Nov 23
Transcripts
APLS
Earnings call transcript
2023 Q4
27 Feb 24
APLS
Earnings call transcript
2023 Q3
1 Nov 23
APLS
Earnings call transcript
2023 Q2
31 Jul 23
APLS
Earnings call transcript
2023 Q1
4 May 23
APLS
Earnings call transcript
2023 Q1
4 May 23
APLS
Earnings call transcript
2022 Q3
8 Nov 22
APLS
Earnings call transcript
2022 Q2
9 Aug 22
APLS
Earnings call transcript
2022 Q1
5 May 22
APLS
Earnings call transcript
2021 Q4
1 Mar 22
APLS
Earnings call transcript
2021 Q3
9 Nov 21
Latest ownership filings
4
Timothy Eugene Sullivan
19 Apr 24
4
A. Sinclair Dunlop
15 Apr 24
4
Pascal Deschatelets
9 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
4
Timothy Eugene Sullivan
2 Apr 24
144
Notice of proposed sale of securities
1 Apr 24
4
A. Sinclair Dunlop
20 Mar 24
144
Notice of proposed sale of securities
19 Mar 24
4
Mark Jeffrey DeLong
19 Mar 24
4
James George Chopas
18 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 453.50 mm | 453.50 mm | 453.50 mm | 453.50 mm | 453.50 mm | 453.50 mm |
Cash burn (monthly) | 54.61 mm | 11.00 mm | 46.67 mm | 50.57 mm | 56.36 mm | 53.13 mm |
Cash used (since last report) | 374.77 mm | 75.45 mm | 320.24 mm | 346.99 mm | 386.76 mm | 364.61 mm |
Cash remaining | 78.73 mm | 378.05 mm | 133.26 mm | 106.51 mm | 66.74 mm | 88.89 mm |
Runway (months of cash) | 1.4 | 34.4 | 2.9 | 2.1 | 1.2 | 1.7 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 258 |
Opened positions | 44 |
Closed positions | 106 |
Increased positions | 120 |
Reduced positions | 63 |
13F shares | Current |
---|---|
Total value | 4.28 tn |
Total shares | 125.50 mm |
Total puts | 2.60 mm |
Total calls | 6.71 mm |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Wellington Management | 15.17 mm | $576.95 bn |
Morningside Venture Investments | 12.81 mm | $0.00 |
Avoro Capital Advisors | 11.11 mm | $422.67 bn |
EcoR1 Capital | 10.90 mm | $414.63 bn |
Vanguard | 9.47 mm | $360.24 bn |
T. Rowe Price Investment Management | 6.52 mm | $248.63 bn |
BLK Blackrock | 5.27 mm | $200.58 bn |
Jennison Associates | 3.54 mm | $134.75 bn |
STT State Street | 3.24 mm | $123.18 bn |
Octagon Capital Advisors | 3.13 mm | $119.07 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Apr 24 | Timothy Eugene Sullivan | Common Stock | Gift | Acquire G | Yes | No | 0 | 14,164 | 0.00 | 70,396 |
18 Apr 24 | Timothy Eugene Sullivan | Common Stock | Gift | Dispose G | No | No | 0 | 14,164 | 0.00 | 79,174 |
12 Apr 24 | A. Sinclair Dunlop | Common Stock | Option exercise | Acquire M | No | No | 13.19 | 1,500 | 19.79 k | 133,518 |
12 Apr 24 | A. Sinclair Dunlop | Stock Option Common Stock | Option exercise | Dispose M | No | No | 13.19 | 1,500 | 19.79 k | 5,500 |
8 Apr 24 | Deschatelets Pascal | Common Stock | Sell | Dispose S | No | Yes | 54.9152 | 4,728 | 259.64 k | 1,115,983 |
8 Apr 24 | Deschatelets Pascal | Common Stock | Sell | Dispose S | No | Yes | 54.1165 | 64,379 | 3.48 mm | 1,120,711 |
8 Apr 24 | Deschatelets Pascal | Common Stock | Option exercise | Acquire M | No | Yes | 3.76 | 69,107 | 259.84 k | 1,185,090 |
8 Apr 24 | Deschatelets Pascal | Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 3.76 | 69,107 | 259.84 k | 37,280 |
1 Apr 24 | Timothy Eugene Sullivan | Common Stock | Sell | Dispose S | No | Yes | 58.66 | 4,000 | 234.64 k | 93,338 |
1 Apr 24 | Timothy Eugene Sullivan | Common Stock | Option exercise | Acquire M | No | Yes | 10.03 | 4,000 | 40.12 k | 97,338 |
News
Wedbush Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $57
17 Apr 24
Expert Ratings For Apellis Pharmaceuticals
15 Apr 24
HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
15 Apr 24
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today
10 Apr 24
Needham Reiterates Buy on Apellis Pharmaceuticals, Maintains $85 Price Target
9 Apr 24
Press releases
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 Apr 24
Investigation Alert: Cummins, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital - Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
19 Mar 24
Investigation Alert Driven Brands Holdings, Apellis Pharmaceuticals, Inspire Medical, and Applied Digital: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below
5 Mar 24
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
Pegcetacoplan (APL-2) by Apellis Pharmaceuticals expected to drive market size of Amyotrophic Lateral Sclerosis
31 Jan 24